Ameristat Pharmaceuticals, Inc.   

Sensipar - sensipar@aipharma.com

Mimpara - mimpara@aipharma.com

 


 

 

 

Sensipar® is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis.

Sensipar® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.


Sensipar® lowers serum calcium. Significant reductions in calcium may lower the threshold for seizures. Secondary hyperparathyroidism patients, particularly those with a history of a seizure disorder, should be carefully monitored for the occurrence of low serum calcium or symptoms of hypocalcemia. The most commonly reported side effects were nausea and vomiting.
 

Mimpara® is the tradename for cinacalcet in Europe and Sensipar® is the tradename for cinacalcet in the US. If you are a European physician prescribing Mimpara® in Europe, please refer to the Mimpara® Prescribing Information.
 

More information is available at www.sensipar.com or www.mimpara.com